Not finding it? Sign in to also search OpenAlex live.
-
Adaptivity and adaptability as design parameters of cognitive worker assistance for enabling agile assembly systems2021 Procedia CIRP article Business, Management and Accounting Product Development and Customization Open access
Peter Burggräf, Matthias Dannapfel, Tobias Adlon, Mateo Kasalo
13citations -
Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial.
Oleg Gluz, Matthias Christgen, Sherko Küemmel, Christine zu Eulenburg, Michael S Braun, Bahriye Aktas, +14 more
1citations -
Myosin II regulates cellular thermo-adaptability and the efficiency of immune responses2025 Developmental Cell article Biochemistry, Genetics and Molecular Biology Cellular Mechanics and Interactions Open access
Alberto Zurita Carpio, Mariona Colomer-Rosell, Bernard Ciraulo, Ronja Molkenbur, Peter Lanzerstorfer, Fabio Pezzano, +15 more
6citations -
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Ulrike Anneliese Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, +43 more
93citations -
The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer2020 Therapeutic Advances in Medical Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Ulrike Anneliese Nitz, Oleg Gluz, Hans Heinrich Kreipe, Matthias Christgen, Sherko Küemmel, Frederick L. Baehner, +16 more
46citations -
De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.2021 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, Michael S Braun, +14 more
21citations -
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Monika Graeser, Felix Hilpert, Katja Krauss, +11 more
18citations -
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta López‐Yurda, Valesca P. Retèl, Marthe S. Paats, +16 more
12citations -
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial2022 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, +21 more
14citations -
Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial2021 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Nadia Harbeck, Oleg Gluz, Sherko Küemmel, Matthias Christgen, Michael S Braun, Bahriye Aktas, +21 more
12citations -
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
Monika Graeser, Simone Schrading, Oleg Gluz, Kevin Strobel, Rachel Würstlein, Sherko Kümmel, +15 more
12citations -
Beyond simple self-healing: How anisotropic nanogels adapt their shape to their environment2022 The Journal of Chemical Physics article Biochemistry, Genetics and Molecular Biology Hydrogels: synthesis, properties, applications
Anne C. Nickel, Alan R. Denton, Judith Elizabeth Houston, Ralf Schweins, Tomás S. Plivelic, Walter H. Richtering, +1 more
6citations